During The European Hematology Association (EHA), Dr. Peggy Lu from Lu Daopei Hospital gave a oral speech concerning CAR-T therapy based on CD7 for relapsed & refractory T cell hematologic malignancies.
T cell malignant tumor is a kind of hematological tumor with high recurrence rate and mortality. The co expression of CD7 by CAR-T cells and malignant T cells will lead to the “cannibalism” of CAR-T cells, which to some extent limits the development of CAR-T cell therapy in T-cell malignant tumors. Here, we have developed a ko7 CAR-T cell that will not produce “cannibalism” through crispr/cas9 gene editing.
From October 2020 to October 2021, a total of 15 patients with acute T-lymphoblastic leukemia (n=10), T-cell lymphoblastic lymphoma (n=3) and mixed phenotype acute leukemia (n=2) were enrolled and received ko7 car-t cell therapy.
In the efficacy evaluation on the 28th day after ko7 CAR-T reinfusion, 15/15 patients (100%) achieved complete remission (CR) with negative minimal residual disease (MRD).